Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

GMAB

Genmab AS (GMAB)

Genmab AS

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:GMAB

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
02/20/2025	8:00AM	Business Wire	EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma	NASDAQ:GMAB	Genmab AS
02/13/2025	1:05PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
02/12/2025	4:43PM	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:GMAB	Genmab AS
02/12/2025	1:06PM	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:GMAB	Genmab AS
02/12/2025	11:20AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
01/29/2025	12:00PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
12/09/2024	12:00PM	Business Wire	Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)	NASDAQ:GMAB	Genmab AS
12/08/2024	11:00AM	Business Wire	Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis	NASDAQ:GMAB	Genmab AS
12/07/2024	7:00PM	Business Wire	Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)	NASDAQ:GMAB	Genmab AS
12/04/2024	11:26AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
12/03/2024	4:45PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
12/03/2024	11:19AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
11/27/2024	12:54PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
11/21/2024	2:56PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
11/05/2024	12:00PM	Business Wire	Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting	NASDAQ:GMAB	Genmab AS
09/15/2024	8:45AM	Business Wire	Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial	NASDAQ:GMAB	Genmab AS
09/11/2024	3:47PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
09/10/2024	4:16PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
08/21/2024	10:50AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
08/19/2024	2:00PM	Business Wire	TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	NASDAQ:GMAB	Genmab AS
08/16/2024	9:00AM	Business Wire	Genmab Announces Changes to its Executive Committee	NASDAQ:GMAB	Genmab AS
08/14/2024	10:48AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
08/13/2024	2:57PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
08/05/2024	6:28AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
07/17/2024	10:00AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
06/28/2024	2:00AM	Business Wire	Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	NASDAQ:GMAB	Genmab AS
06/26/2024	7:08PM	Business Wire	EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)	NASDAQ:GMAB	Genmab AS
06/12/2024	3:50PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
06/11/2024	3:30PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
06/10/2024	12:51PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS

Showing the most relevant articles for your search:NASDAQ:GMAB

1 2 3 4 5 6 7 8 9 10 Next >>

AMC Entertainment

Asia Broadband (PK)

Voip Pal Com (QB)

Kraig Biocraft Laborator... (QB)

Bioelectronics (PK)

Intergrated Cannabis Sol... (PK)

Lightwave Logic

Elite Pharmaceuticals (QB)

Digital Brand Media and ... (PK)

NioCorp Developments

Anavex Life Sciences

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions